Quarterly report pursuant to Section 13 or 15(d)

Investment in Saneron CCEL Therapeutics, Inc. (''Saneron'') - Additional Information (Detail)

v2.4.0.8
Investment in Saneron CCEL Therapeutics, Inc. (''Saneron'') - Additional Information (Detail) (USD $)
3 Months Ended 6 Months Ended 12 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended
May 31, 2014
Nov. 30, 2013
May 31, 2014
Saneron [Member]
May 31, 2014
Saneron [Member]
Installment
Nov. 30, 2013
Saneron [Member]
May 31, 2014
Saneron [Member]
Common Stock and Warrant Awards [Member]
May 31, 2013
Saneron [Member]
Common Stock and Warrant Awards [Member]
May 31, 2014
Saneron [Member]
Common Stock and Warrant Awards [Member]
May 31, 2013
Saneron [Member]
Common Stock and Warrant Awards [Member]
May 31, 2014
Saneron [Member]
Valuation Allowance Investment [Member]
May 31, 2014
Saneron [Member]
Valuation Allowance Investment [Member]
May 31, 2014
Saneron [Member]
Initial Loan [Member]
Installment
May 31, 2014
Saneron [Member]
Additional Loan [Member]
Installment
Investments In Affiliates [Line Items]                          
Ownership interest     34.00% 34.00%                  
Equity method investment $ 684,000 $ 684,000 $ 684,000 $ 684,000 $ 684,000                
Equity method investment, other than temporary impairment loss       0 0                
Goodwill impairment loss       0 0                
Loan Saneron in quarterly payments an aggregate amount     300,000 300,000                  
Initial loan amount                       150,000 150,000
Additional quarterly payments       3               4 4
Quarterly installments per quarter                       37,500 37,500
Date of maturity       5 years                  
Quarterly installments per quarter       37,500                  
Equity in losses     76,076 189,651   38,576 38,450 77,151 76,900        
Valuation allowances on investment                   37,500 112,500    
Value of treasury stock $ 4,333,401 $ 2,926,123 $ 485,000 $ 485,000 $ 485,000